Veracity Capital LLC Purchases 3,213 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Veracity Capital LLC boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 58.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,733 shares of the biopharmaceutical company’s stock after acquiring an additional 3,213 shares during the period. Veracity Capital LLC’s holdings in Gilead Sciences were worth $807,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of GILD. nVerses Capital LLC purchased a new position in Gilead Sciences during the 3rd quarter valued at about $25,000. Decker Retirement Planning Inc. purchased a new position in shares of Gilead Sciences during the fourth quarter valued at approximately $29,000. Valued Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 161 shares in the last quarter. Strategic Investment Solutions Inc. IL purchased a new stake in Gilead Sciences in the second quarter worth $33,000. Finally, Friedenthal Financial bought a new stake in Gilead Sciences in the third quarter valued at $50,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 0.1 %

Shares of NASDAQ:GILD opened at $92.92 on Friday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $98.90. The company has a market cap of $115.80 billion, a P/E ratio of 1,032.44, a PEG ratio of 1.31 and a beta of 0.18. The stock’s fifty day moving average price is $91.63 and its 200-day moving average price is $84.63.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. During the same quarter in the prior year, the business earned $2.29 EPS. The business’s revenue for the quarter was up 7.0% compared to the same quarter last year. Sell-side analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were paid a dividend of $0.77 per share. The ex-dividend date was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.31%. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

Analysts Set New Price Targets

Several research analysts have commented on GILD shares. Citigroup assumed coverage on shares of Gilead Sciences in a report on Thursday, November 14th. They issued a “buy” rating and a $125.00 price objective for the company. Leerink Partners upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and raised their price objective for the stock from $74.00 to $96.00 in a report on Monday, October 21st. Maxim Group cut Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Mizuho increased their target price on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Finally, Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and an average target price of $97.96.

Insider Activity

In other news, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the transaction, the director now owns 8,920 shares in the company, valued at $815,198.80. This represents a 43.21 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 456,234 shares of company stock valued at $42,130,461 in the last ninety days. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.